BioTime Inc. (BTX)

2.51
0.10 4.15
AMEX : Health Technology
Prev Close 2.41
Open 2.45
Day Low/High 2.42 / 2.53
52 Wk Low/High 1.98 / 3.16
Volume 256.92K
Avg Volume 518.20K
Exchange AMEX
Shares Outstanding 126.88M
Market Cap 321.00M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the second quarter ended June 30, 2018 and recent corporate accomplishments.

BioTime To Receive $43 Million From Juvenescence

BioTime To Receive $43 Million From Juvenescence

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced a new strategic alignment between AgeX Therapeutics and Juvenescence Limited, a global leader in developing therapeutics focused...

BioTime Announces The Start Of An Investigator Initiated Study Of Premvia™ Designed And Conducted By Dr. Gordon H. Sasaki

BioTime Announces The Start Of An Investigator Initiated Study Of Premvia™ Designed And Conducted By Dr. Gordon H. Sasaki

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported that Gordon H.

BioTime Announces Distribution Ratio For Distribution Of AgeX Therapeutics Shares

BioTime Announces Distribution Ratio For Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the distribution ratio for the distribution of AgeX Therapeutics shares owned by BioTime on a...

Data From BioTime's OpRegen® Program To Be Presented At AAO 2018

Data From BioTime's OpRegen® Program To Be Presented At AAO 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract "PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD...

BioTime To Announce Second Quarter 2018 Results On August 2, 2018

BioTime To Announce Second Quarter 2018 Results On August 2, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.

BioTime Announces July 31, 2018 Record Date For The Distribution Of AgeX Therapeutics Shares

BioTime Announces July 31, 2018 Record Date For The Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for the distribution of AgeX Therapeutics ("AgeX") shares owned by BioTime on...

BioTime Awarded Grant From The NIH

BioTime Awarded Grant From The NIH

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes...

BioTime Licenses GMP Cell Line To Goliver Therapeutics

BioTime Licenses GMP Cell Line To Goliver Therapeutics

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France-based company focused on addressing liver diseases with...

AgeX Therapeutics Closes On $5 Million Strategic Investment From Juvenescence

AgeX Therapeutics Closes On $5 Million Strategic Investment From Juvenescence

AgeX Therapeutics, Inc., a subsidiary of  BioTime, Inc.

BioTime Announces Submission Of Draft Registration Statement For A Proposed Distribution Of Its AgeX Shares

BioTime Announces Submission Of Draft Registration Statement For A Proposed Distribution Of Its AgeX Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics, Inc., a subsidiary of  BioTime, Inc.

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen ®, with the addition of two new U.

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments.

AgeX Announces NIH Grant Award

AgeX Announces NIH Grant Award

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen ® for dry-AMD, was presented at the Association for Research in...

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADES, ALCO, ARTX, EVI, FNJN, INXN, KLXI, KODK, TGEN, XOXO Downgrades: BTX, CCRN, NFBK, WEB Initiations: METC Read on to get TheStreet Quant Ratings' detailed report:

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Investors considering a purchase of BioTime Inc stock, but cautious about paying the going market price of $2.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market...

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the...

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and...

TheStreet Quant Rating: D (Sell)